Cortical Binding of Pittsburgh Compound B, an Endophenotype for Genetic Studies of Alzheimer's Disease

Biological Psychiatry

Volumn 67, Issue 6, 2010, Pages 581-583

  Hinrichs, Anthony L ^a   Mintun, Mark A ^a   Head, Denise ^a,b   Fagan, Anne M ^a   Holtzman, David M ^a   Morris, John C ^a   Goate, Alison M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; genetics; imaging; PIB

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; PITTSBURGH COMPOUND B; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BIOLOGICAL TRAIT; BRAIN CORTEX; BRAIN REGION; CEREBROSPINAL FLUID; FEMALE; GENETIC TRAIT; GENETICS; GENOTYPE; HERITABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANILINE COMPOUNDS; APOLIPOPROTEIN E4; CARBON RADIOISOTOPES; CEREBRAL CORTEX; FAMILY HEALTH; HUMANS; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS; THIAZOLES;

EID: 77149159754     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2009.09.012     Document Type: Article

References (20)

1. Pastor P., and Goate A.M. Molecular genetics of Alzheimer's disease. Curr Psychiatry Rep 6 (2004) 125-133
2. Daw E.W., Heath S.C., and Wijsman E.M. Multipoint oligogenic analysis of age-at-onset data with applications to Alzheimer's disease pedigrees. Am J Hum Genet 64 (1999) 839-851
3. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer's disease and relation to apolipoprotein E genotype. Arch Neurol 55 (1998) 937-945
4. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA 289 (2003) 2094-2103
5. Mathis C.A., Wang Y., Holt D.P., Huang G.F., Debnath M.L., and Klunk W.E. Synthesis and evaluation of 11c-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46 (2003) 2740-2754
6. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004) 306-319
7. Villemagne V.L., Pike K.E., Darby D., Maruff P., Savage G., Ng S., et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46 (2008) 1688-1697
8. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59 (2006) 512-519
9. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., et al. (11C)PIB in a nondemented population: Potential antecedent marker of Alzheimer's disease. Neurology 67 (2006) 446-452
10. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., and Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64 (2007) 343-349
11. de Leon M.J., Mosconi L., Blennow K., DeSanti S., Zinkowski R., Mehta P.D., et al. Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci 1097 (2007) 114-145
12. Li G., Sokal I., Quinn J.F., Leverenz J.B., Brodey M., Schellenberg G.D., et al. CSF tau/abeta42 ratio for increased risk of mild cognitive impairment: A follow-up study. Neurology 69 (2007) 631-639
13. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106 (2009) 6820-6825
14. Buckner R.L., Head D., Parker J., Fotenos A.F., Marcus D., Morris J.C., et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: Reliability and validation against manual measurement of total intracranial volume. Neuroimage 23 (2004) 724-738
15. Mintun M.A., Raichle M.E., Kilbourn M.R., Wooten G.F., and Welch M.J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15 (1984) 217-227
16. Davis P.B., Morris J.C., and Grant E. Brief screening tests versus clinical staging in senile dementia of the Alzheimer type. J Am Geriatr Soc 38 (1990) 129-135
17. Katzman R., Brown T., Fuld P., Peck A., Schechter R., and Schimmel H. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry 140 (1983) 734-739
18. Morris J.C. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43 (1993) 2412-2414
19. The Human Genetic Analysis Resource. S.A.G.E. Statistical Analysis for Genetic Epidemiology, release 5.4.0 (2007). http://darwin.cwru.edu/ Accessed August 30, 2009
20. Keen K.J., and Elston R.C. Robust asymptotic sampling theory for correlations in pedigrees. Stat Med 22 (2003) 3229-3247